276 related articles for article (PubMed ID: 28004853)
1. Ustekinumab therapy for Crohn's disease during pregnancy: a case report and review of the literature.
Cortes X; Borrás-Blasco J; Antequera B; Fernandez-Martinez S; Casterá E; Martin S; Molés JR
J Clin Pharm Ther; 2017 Apr; 42(2):234-236. PubMed ID: 28004853
[TBL] [Abstract][Full Text] [Related]
2. Drug Levels in the Maternal Serum, Cord Blood and Breast Milk of a Ustekinumab-Treated Patient with Crohn's Disease.
Klenske E; Osaba L; Nagore D; Rath T; Neurath MF; Atreya R
J Crohns Colitis; 2019 Feb; 13(2):267-269. PubMed ID: 30388211
[TBL] [Abstract][Full Text] [Related]
3. Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease.
Dubinsky M; Ma C; Griffith J; Crowell M; Neimark E; Kligys K; O'Connell T
Adv Ther; 2023 Sep; 40(9):3896-3911. PubMed ID: 37368103
[TBL] [Abstract][Full Text] [Related]
4. [Clinical remission and transmural healing of ustekinumab in patients with Crohn's disease].
Wu Y; Xu Y; Zhang G; Zhang Y; Wang J; You P; Peng T; Liu Y; Chen N
Beijing Da Xue Xue Bao Yi Xue Ban; 2024 Apr; 56(2):253-259. PubMed ID: 38595241
[TBL] [Abstract][Full Text] [Related]
5. Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE).
Eberl A; Hallinen T; Af Björkesten CG; Heikkinen M; Hirsi E; Kellokumpu M; Koskinen I; Moilanen V; Nielsen C; Nuutinen H; Suhonen UM; Utriainen K; Vihriälä I; Soini E; Wennerström C; Nissinen R; Borsi A; Koivunen M; Tillonen J; Sipponen T
Scand J Gastroenterol; 2019 Jun; 54(6):718-725. PubMed ID: 31184512
[No Abstract] [Full Text] [Related]
6. Maternal and Neonatal Outcomes in Vedolizumab- and Ustekinumab-Exposed Pregnancies: Results From the PIANO Registry.
Chugh R; Long MD; Jiang Y; Weaver KN; Beaulieu DB; Scherl EJ; Mahadevan U
Am J Gastroenterol; 2024 Mar; 119(3):468-476. PubMed ID: 37796648
[TBL] [Abstract][Full Text] [Related]
7. Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn's disease: a Chinese real-world study.
Yao JY; Zhang M; Wang W; Peng X; Zhao JZ; Liu T; Li ZW; Sun HT; Hu P; Zhi M
BMC Gastroenterol; 2021 Oct; 21(1):380. PubMed ID: 34663208
[TBL] [Abstract][Full Text] [Related]
8. Real-world Comparative Effectiveness of Ustekinumab vs Anti-TNF in Crohn's Disease With Propensity Score Adjustment: Induction Phase Results From the Prospective, Observational RUN-CD Study.
Bokemeyer B; Plachta-Danielzik S; di Giuseppe R; Mohl W; Teich N; Hoffstadt M; Schweitzer A; von der Ohe M; Gauss A; Atreya R; Krause T; Blumenstein I; Hartmann P; Schreiber S
Inflamm Bowel Dis; 2023 Nov; 29(11):1741-1750. PubMed ID: 36633301
[TBL] [Abstract][Full Text] [Related]
9. Long-term effectiveness of ustekinumab comparable to antitumor necrosis factor agents in patients with Crohn's disease.
Shiga H; Tarasawa K; Moroi R; Makuuchi M; Takahashi T; Shimoyama Y; Kuroha M; Kakuta Y; Fushimi K; Fujimori K; Kinouchi Y; Masamune A
J Gastroenterol Hepatol; 2022 Nov; 37(11):2105-2112. PubMed ID: 36059265
[TBL] [Abstract][Full Text] [Related]
10. Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn's disease: A systematic review and meta-analysis.
Yoshihara T; Shinzaki S; Amano T; Iijima H; Takehara T; Inoue N; Uchino M; Esaki M; Kobayashi T; Saruta M; Sugimoto K; Nakamura S; Hata K; Hirai F; Hiraoka S; Fujii T; Matsuura M; Matsuoka K; Watanabe K; Nakase H; Watanabe M
J Gastroenterol Hepatol; 2021 Jul; 36(7):1744-1753. PubMed ID: 33450096
[TBL] [Abstract][Full Text] [Related]
11. [Analysis on the efficacy of dual vein induction therapy of Ustekinumab in complex perianal fistulizing Crohn's disease].
Zhang DL; Shao XX; Hu DY; Lin DP; Wu H; Jiang Y
Zhonghua Yi Xue Za Zhi; 2023 Nov; 103(41):3301-3306. PubMed ID: 37926575
[No Abstract] [Full Text] [Related]
12. Ustekinumab in Crohn's disease: effectiveness and safety in clinical practice.
Saldaña Dueñas C; Rullán Iriarte M; Elosua González A; Rodríguez Gutiérrez C; Rubio Iturria S; Nantes Castillejo Ó
Gastroenterol Hepatol; 2020 Nov; 43(9):497-505. PubMed ID: 32703654
[TBL] [Abstract][Full Text] [Related]
13. Persistence, Dose Titration, and Health Care Resource Utilization Among Crohn's Disease Patients Treated With Ustekinumab: A Real-World Analysis in the United States.
Obando C; Ding Z; Muser E; Vaidya N; Qiang W; Sun X; Wang H; Mallampati R; Xie L
Adv Ther; 2020 May; 37(5):2127-2143. PubMed ID: 32193810
[TBL] [Abstract][Full Text] [Related]
14. Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn's Disease.
Painchart C; Brabant S; Duveau N; Nachury M; Desreumaux P; Branche J; Gérard R; Prevost CLD; Wils P; Lambin T; Boualit M; Labalette M; Pariente B
Dig Dis Sci; 2020 May; 65(5):1445-1452. PubMed ID: 31599389
[TBL] [Abstract][Full Text] [Related]
15. The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies.
Narula N; Aruljothy A; Wong ECL; Homenauth R; Alshahrani AA; Marshall JK; Reinisch W
United European Gastroenterol J; 2021 Jun; 9(5):581-589. PubMed ID: 34077627
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of a Clinical Decision Support Tool for Ustekinumab to Predict Clinical Remission and Relapse in Patients With Crohn's Disease: A Multicenter Observational Study.
Park J; Chun J; Yoon H; Cheon JH
Inflamm Bowel Dis; 2023 Apr; 29(4):548-554. PubMed ID: 35670522
[TBL] [Abstract][Full Text] [Related]
17. Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn's Disease.
Straatmijer T; Biemans VBC; Moes DJAR; Hoentjen F; Ter Heine R; Maljaars PWJ; Theeuwen R; Pierik M; Duijvestein M; van der Meulen-de Jong AE;
Dig Dis Sci; 2023 Jun; 68(6):2647-2657. PubMed ID: 36920666
[TBL] [Abstract][Full Text] [Related]
18. Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn's disease.
Hirayama H; Morita Y; Imai T; Takahashi K; Yoshida A; Bamba S; Inatomi O; Andoh A
BMC Gastroenterol; 2022 Apr; 22(1):195. PubMed ID: 35448957
[TBL] [Abstract][Full Text] [Related]
19. The effectiveness of ustekinumab and vedolizumab as third-line biologic therapy in patients with Crohn's disease.
Macaluso FS; Grova M; Saladino M; Cappello M; Demarzo MG; Privitera AC; Giangreco E; Garufi S; Renna S; Casà A; Ventimiglia M; Fries W; Orlando A;
Dig Liver Dis; 2023 Apr; 55(4):471-477. PubMed ID: 36127230
[TBL] [Abstract][Full Text] [Related]
20. Utility of Therapeutic Drug Monitoring for Tumor Necrosis Factor Antagonists and Ustekinumab in Postoperative Crohn's Disease.
Pan Y; Ahmed W; Mahtani P; Wong R; Longman R; Jeremy Lukin D; Scherl EJ; Battat R
Inflamm Bowel Dis; 2022 Dec; 28(12):1865-1871. PubMed ID: 35212368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
